$CBT
CABOT CORP

2024 Q1 Form 10-Q Financial Statement

#000095017024012680 Filed on February 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $1.019B $958.0M
YoY Change -1.36% -0.73%
Cost Of Revenue $773.0M $740.0M
YoY Change -6.08% -5.61%
Gross Profit $246.0M $218.0M
YoY Change 17.14% 20.44%
Gross Profit Margin 24.14% 22.76%
Selling, General & Admin $75.00M $67.00M
YoY Change 13.64% 11.67%
% of Gross Profit 30.49% 30.73%
Research & Development $15.00M $15.00M
YoY Change 0.0% 15.38%
% of Gross Profit 6.1% 6.88%
Depreciation & Amortization $37.00M $41.00M
YoY Change 2.78% 17.14%
% of Gross Profit 15.04% 18.81%
Operating Expenses $90.00M $82.00M
YoY Change 11.11% 12.33%
Operating Profit $156.0M $136.0M
YoY Change 20.93% 29.52%
Interest Expense $21.00M $22.00M
YoY Change -8.7% 0.0%
% of Operating Profit 13.46% 16.18%
Other Income/Expense, Net -$1.000M -$29.00M
YoY Change -80.0% 480.0%
Pretax Income $142.0M $94.00M
YoY Change 29.09% 11.9%
Income Tax $47.00M $34.00M
% Of Pretax Income 33.1% 36.17%
Net Earnings $84.00M $50.00M
YoY Change 12.0% -7.41%
Net Earnings / Revenue 8.24% 5.22%
Basic Earnings Per Share $1.50 $0.88
Diluted Earnings Per Share $1.49 $0.88
COMMON SHARES
Basic Shares Outstanding 55.43M 55.31M
Diluted Shares Outstanding 55.80M 55.80M

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.0M $244.0M
YoY Change 0.49% 28.42%
Cash & Equivalents $206.0M $244.0M
Short-Term Investments
Other Short-Term Assets $104.0M $105.0M
YoY Change -28.28% -17.32%
Inventory $551.0M $617.0M
Prepaid Expenses
Receivables $744.0M $726.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.605B $1.692B
YoY Change -7.86% -6.0%
LONG-TERM ASSETS
Property, Plant & Equipment $1.427B $1.444B
YoY Change 5.47% 10.74%
Goodwill $137.0M $138.0M
YoY Change 0.74% 3.76%
Intangibles
YoY Change
Long-Term Investments $22.00M $21.00M
YoY Change 0.0% 0.0%
Other Assets $183.0M $173.0M
YoY Change 10.91% 1.76%
Total Long-Term Assets $1.991B $2.003B
YoY Change 12.04% 15.45%
TOTAL ASSETS
Total Short-Term Assets $1.605B $1.692B
Total Long-Term Assets $1.991B $2.003B
Total Assets $3.596B $3.695B
YoY Change 2.19% 4.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $587.0M $585.0M
YoY Change -3.61% -7.14%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $88.00M $206.0M
YoY Change -65.89% -33.97%
Long-Term Debt Due $8.000M $8.000M
YoY Change 0.0% 14.29%
Total Short-Term Liabilities $718.0M $830.0M
YoY Change -20.58% -15.65%
LONG-TERM LIABILITIES
Long-Term Debt $1.088B $1.098B
YoY Change -0.55% 0.64%
Other Long-Term Liabilities $245.0M $241.0M
YoY Change 6.06% 2.12%
Total Long-Term Liabilities $1.333B $1.339B
YoY Change 0.6% 0.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $718.0M $830.0M
Total Long-Term Liabilities $1.333B $1.339B
Total Liabilities $2.051B $2.169B
YoY Change -7.99% -6.14%
SHAREHOLDERS EQUITY
Retained Earnings $1.632B $1.582B
YoY Change 20.0% 20.4%
Common Stock $55.00M $55.00M
YoY Change -1.79% -3.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.367B $1.329B
YoY Change
Total Liabilities & Shareholders Equity $3.596B $3.695B
YoY Change 2.19% 4.53%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income $84.00M $50.00M
YoY Change 12.0% -7.41%
Depreciation, Depletion And Amortization $37.00M $41.00M
YoY Change 2.78% 17.14%
Cash From Operating Activities $176.0M $105.0M
YoY Change 8.64% 101.92%
INVESTING ACTIVITIES
Capital Expenditures $43.00M $54.00M
YoY Change -15.69% 54.29%
Acquisitions
YoY Change
Other Investing Activities $2.000M $0.00
YoY Change -50.0% -100.0%
Cash From Investing Activities -$41.00M -$54.00M
YoY Change -12.77% 217.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $1.000M
YoY Change -83.33%
Cash From Financing Activities -166.0M -29.00M
YoY Change 40.68% -68.48%
NET CHANGE
Cash From Operating Activities 176.0M 105.0M
Cash From Investing Activities -41.00M -54.00M
Cash From Financing Activities -166.0M -29.00M
Net Change In Cash -31.00M 6.000M
YoY Change 933.33% -137.5%
FREE CASH FLOW
Cash From Operating Activities $176.0M $105.0M
Capital Expenditures $43.00M $54.00M
Free Cash Flow $133.0M $51.00M
YoY Change 19.82% 200.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0000016040
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
6000000
CY2023Q4 us-gaap Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration
SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q3 us-gaap Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration
SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
1-5667
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
Cabot Corporation
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2271897
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
Two Seaport Lane
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210-2019
CY2023Q4 dei City Area Code
CityAreaCode
617
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
345-0100
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, $1 par value per share
CY2023Q4 dei Trading Symbol
TradingSymbol
CBT
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55430710
CY2023Q4 us-gaap Revenues
Revenues
958000000
CY2022Q4 us-gaap Revenues
Revenues
965000000
CY2023Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
740000000
CY2022Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
784000000
CY2023Q4 us-gaap Gross Profit
GrossProfit
218000000
CY2022Q4 us-gaap Gross Profit
GrossProfit
181000000
CY2023Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67000000
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60000000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15000000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13000000
CY2022Q4 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-3000000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
136000000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
105000000
CY2023Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
9000000
CY2022Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
6000000
CY2023Q4 us-gaap Interest Expense
InterestExpense
22000000
CY2022Q4 us-gaap Interest Expense
InterestExpense
22000000
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000000
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
94000000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
84000000
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000000
CY2023Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
CY2022Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2000000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
61000000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
66000000
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
12000000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
50000000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
54000000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55300000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56300000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55800000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56700000
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.88
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.94
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.88
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
CY2023Q4 us-gaap Profit Loss
ProfitLoss
61000000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
66000000
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
62000000
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
88000000
CY2023Q4 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1000000
CY2022Q4 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1000000
CY2023Q4 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1000000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
61000000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
87000000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
122000000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
153000000
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
12000000
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
4000000
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
6000000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
15000000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
18000000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
107000000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
135000000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244000000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
238000000
CY2023Q4 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
3000000
CY2023Q3 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
2000000
CY2023Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
726000000
CY2023Q3 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
695000000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
154000000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
148000000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
398000000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
374000000
CY2023Q4 us-gaap Other Inventory
OtherInventory
65000000
CY2023Q3 us-gaap Other Inventory
OtherInventory
63000000
CY2023Q4 us-gaap Inventory Net
InventoryNet
617000000
CY2023Q3 us-gaap Inventory Net
InventoryNet
585000000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
105000000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
108000000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1692000000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1626000000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3936000000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3827000000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2492000000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2415000000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1444000000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000000
CY2023Q4 us-gaap Goodwill
Goodwill
138000000
CY2023Q3 us-gaap Goodwill
Goodwill
134000000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
21000000
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
20000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
61000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
60000000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
166000000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
180000000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
173000000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000000
CY2023Q4 us-gaap Assets
Assets
3695000000
CY2023Q3 us-gaap Assets
Assets
3604000000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
206000000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
174000000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
585000000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
600000000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
31000000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
40000000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
830000000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
822000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1098000000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1094000000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
51000000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
50000000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
241000000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
231000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55560648
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55379636
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55424816
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55243804
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
55000000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
55000000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
135832
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
135832
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3000000
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3000000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1582000000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1574000000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-305000000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-362000000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1329000000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1264000000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
146000000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
143000000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1475000000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1407000000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3695000000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3604000000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
61000000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
66000000
CY2023Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000000
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35000000
CY2022Q4 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-3000000
CY2022Q4 cbt Gain Loss On Sale Of Land
GainLossOnSaleOfLand
1000000
CY2023Q4 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
7000000
CY2023Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
CY2022Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2000000
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
6000000
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
6000000
CY2023Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-37000000
CY2022Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4000000
CY2023Q4 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1000000
CY2022Q4 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2000000
CY2023Q4 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
7000000
CY2022Q4 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-80000000
CY2023Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19000000
CY2022Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14000000
CY2023Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2000000
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12000000
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20000000
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-100000000
CY2023Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-10000000
CY2022Q4 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-10000000
CY2023Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11000000
CY2022Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3000000
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
105000000
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
52000000
CY2023Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000000
CY2022Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000000
CY2022Q4 us-gaap Proceeds From Sale Of Land Held For Use
ProceedsFromSaleOfLandHeldForUse
7000000
CY2022Q4 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
6000000
CY2022Q4 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000000
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000000
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000000
CY2022Q4 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
11000000
CY2023Q4 us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
32000000
CY2022Q4 us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
-48000000
CY2023Q4 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
CY2022Q4 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6000000
CY2023Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
33000000
CY2022Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
17000000
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000000
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3000000
CY2023Q4 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
12000000
CY2022Q4 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
14000000
CY2023Q4 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22000000
CY2022Q4 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
21000000
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-29000000
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-92000000
CY2023Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000000
CY2022Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41000000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
238000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206000000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244000000
CY2023Q4 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">E. Contingencies</span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Respirator Liabilities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cabot has exposure in connection with a safety respiratory products business that a subsidiary acquired from American Optical Corporation (“AO”) in an April 1990 asset purchase transaction. The subsidiary manufactured respirators under the AO brand and disposed of that business in July 1995. In connection with its acquisition of the business, the subsidiary agreed, in certain circumstances, to assume a portion of AO’s liabilities, including costs of legal fees together with amounts paid in settlements and judgments, allocable to AO respiratory products used prior to the 1990 purchase by the Cabot subsidiary. In exchange for the subsidiary’s assumption of certain of AO’s respirator liabilities, AO agreed to provide to the subsidiary the benefits of: (i) AO’s insurance coverage for the period prior to the 1990 acquisition and (ii) a former owner’s indemnity of AO holding it harmless from any liability allocable to AO respiratory products used prior to May 1982. As more fully described in the 2023 10-K, the respirator liabilities generally involve claims for personal injury, including asbestosis, silicosis and coal worker’s pneumoconiosis, allegedly resulting from the use of respirators that are alleged to have been negligently designed and/or labeled. At no time did this respiratory product line represent a significant portion of the respirator market. In addition to Cabot’s subsidiary, other parties are responsible for significant portions of the costs of these respirator liabilities (as defined in the 2023 10-K, the “Payor Group”).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cabot has a reserve to cover its expected share of liabilities for pending and future respirator liability claims, which is included in Other liabilities and Accounts payable and accrued liabilities on the Consolidated Balance Sheets. The Company expects these liabilities to be incurred over a number of years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The reserve balance was $</span><span style="font-size:10pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">at both December 31, 2023 and September 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company’s current estimate of the cost of its share of pending and future respirator liability claims is based on facts and circumstances existing at this time, including the number and nature of the remaining claims. Developments that could affect the Company’s estimate include, but are not limited to, (i) significant changes in the number of future claims, (ii) changes in the rate of dismissals without payment of pending claims, (iii) significant changes in the average cost of resolving claims, including potential settlements of groups of claims, (iv) significant changes in the legal costs of defending these claims, (v) changes in the nature of claims received or changes in our assessment of the viability of these claims, (vi) trial and appellate outcomes, (vii) changes in the law and procedure applicable to these claims, (viii) the financial viability of the parties that contribute to the payment of respirator claims, (ix) exhaustion or changes in the recoverability of the insurance coverage maintained by certain members of the Payor Group, or a change in the availability of the indemnity provided by a former owner of AO, (x) changes in the allocation of costs among the various parties paying legal and settlement costs, and (xi) a determination that the assumptions that were used to estimate Cabot’s share of liability are no longer reasonable. The Company cannot determine the impact of these potential developments on its current estimate of its share of liability for existing and future claims. Because reserves are limited to amounts that are probable and estimable as of a relevant measurement date, and there is inherent difficulty in projecting the impact of potential developments on Cabot’s share of liability for these existing and future claims, it is reasonably possible that the liabilities for existing and future claims could change in the near term and that change could be material.</span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Other Matters</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company has various other lawsuits, claims and contingent liabilities arising in the ordinary course of its business and with respect to its divested businesses. The Company does not believe that any of these matters will have a material adverse effect on its financial position; however, litigation is inherently unpredictable. Cabot could incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material impact on its results of operations in the period in which the amounts are accrued or its cash flows in the period in which the amounts are paid.</span></p>
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190000000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1407000000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
61000000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
61000000
CY2023Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.40
CY2023Q4 us-gaap Dividends
Dividends
22000000
CY2023Q4 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
12000000
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7000000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2023Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
33000000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1475000000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1032000000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
66000000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
87000000
CY2022Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2022Q4 us-gaap Dividends
Dividends
21000000
CY2022Q4 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
2000000
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000000
CY2022Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
17000000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1159000000
CY2023Q3 us-gaap Goodwill
Goodwill
134000000
CY2023Q4 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
4000000
CY2023Q4 us-gaap Goodwill
Goodwill
138000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
104000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
43000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
61000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
101000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
60000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6000000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Investment Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
1000000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Investment Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
1000000
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000000
CY2023Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.36
CY2022Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.24
CY2023Q4 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
7000000
CY2022Q4 cbt Net Discrete Tax Benefits Charges Related To Tax Settlements
NetDiscreteTaxBenefitsChargesRelatedToTaxSettlements
3000000
CY2022Q4 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
CY2023Q4 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1000000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
50000000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
54000000
CY2023Q4 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000
CY2022Q4 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
49000000
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
53000000
CY2023Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
56400000
CY2022Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
57600000
CY2023Q4 cbt Participating Securities
ParticipatingSecurities
1100000
CY2022Q4 cbt Participating Securities
ParticipatingSecurities
1300000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55300000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56300000
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.88
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.94
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
49000000
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
53000000
CY2023Q4 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000
CY2022Q4 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000
CY2023Q4 cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-1000000
CY2022Q4 cbt Adjusted Earnings Loss Allocated To Participating Securities
AdjustedEarningsLossAllocatedToParticipatingSecurities
-1000000
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
49000000
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
53000000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55300000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56300000
CY2023Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
500000
CY2022Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
400000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55800000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56700000
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.88
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
50000000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
54000000
CY2023Q4 us-gaap Dividends Common Stock
DividendsCommonStock
22000000
CY2022Q4 us-gaap Dividends Common Stock
DividendsCommonStock
21000000
CY2023Q4 us-gaap Undistributed Earnings
UndistributedEarnings
28000000
CY2022Q4 us-gaap Undistributed Earnings
UndistributedEarnings
33000000
CY2023Q4 cbt Undistributed Loss Earnings Allocated To Common Shareholders
UndistributedLossEarningsAllocatedToCommonShareholders
27000000
CY2022Q4 cbt Undistributed Loss Earnings Allocated To Common Shareholders
UndistributedLossEarningsAllocatedToCommonShareholders
32000000
CY2023Q4 cbt Undistributed Loss Earnings Allocated To Participating Shareholders
UndistributedLossEarningsAllocatedToParticipatingShareholders
1000000
CY2022Q4 cbt Undistributed Loss Earnings Allocated To Participating Shareholders
UndistributedLossEarningsAllocatedToParticipatingShareholders
1000000
CY2023Q4 us-gaap Undistributed Earnings
UndistributedEarnings
28000000
CY2022Q4 us-gaap Undistributed Earnings
UndistributedEarnings
33000000
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
330331
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
86782
CY2023Q4 us-gaap Restructuring Charges
RestructuringCharges
9000000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q4 us-gaap Restructuring Charges
RestructuringCharges
9000000
CY2023Q4 cbt Costs Charged Against Assets Liabilities
CostsChargedAgainstAssetsLiabilities
-6000000
CY2023Q4 us-gaap Payments For Restructuring
PaymentsForRestructuring
1000000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
2000000
CY2022Q4 cbt Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2022Q4 cbt Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q4 cbt Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2022Q4 cbt Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q4 cbt Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2023Q4 cbt Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2023Q4 cbt Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2023Q4 cbt Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2023Q4 us-gaap Supplier Finance Program Obligation Current
SupplierFinanceProgramObligationCurrent
17000000
CY2023Q3 us-gaap Supplier Finance Program Obligation Current
SupplierFinanceProgramObligationCurrent
17000000
CY2023Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q4 us-gaap Revenues
Revenues
958000000
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
94000000
CY2022Q4 us-gaap Revenues
Revenues
965000000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
84000000
CY2023Q4 us-gaap Revenues
Revenues
958000000
CY2022Q4 us-gaap Revenues
Revenues
965000000

Files In Submission

Name View Source Status
0000950170-24-012680-index-headers.html Edgar Link pending
0000950170-24-012680-index.html Edgar Link pending
0000950170-24-012680.txt Edgar Link pending
0000950170-24-012680-xbrl.zip Edgar Link pending
cbt-20231231.htm Edgar Link pending
cbt-20231231.xsd Edgar Link pending
cbt-ex31_1.htm Edgar Link pending
cbt-ex31_2.htm Edgar Link pending
cbt-ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
cbt-20231231_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable